GlassScriptPhysician profile
Starr Lucy Whittaker
NPI 1457715401
$8,370.29
in general payments reported to CMS, 2019-2025
35 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.87 · 2020: $847 · 2021: $1,211 · 2022: $1,205 · 2023: $1,776 · 2024: $1,370 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,264.63 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,171.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,043.23 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.38 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $703.16 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $600.65 | 2021-2025 | |
| Astellas Pharma US INC | $440.11 | 2020-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $355.44 | 2020-2025 | |
| Abbott Laboratories | $336.73 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $269.53 | 2020-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $185.49 | 2019-2025 | Verquvo, Belsomra, Steglujan |
| Janssen Pharmaceuticals, INC | $181.64 | 2020-2022 | |
| Abbvie INC. | $181.47 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $136.95 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $130.16 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $101.22 | 2021-2023 | Nexletol |
| Sumitomo Pharma America, INC. | $76.46 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $63.29 | 2023 | Quviviq |
| Dexcom, INC. | $52.42 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $41.76 | 2022-2024 | Gvoke Hypopen |
| Philips North America LLC | $30.33 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| Radius Health, INC. | $30.16 | 2025 | Tymlos |
| Inspire Medical Systems, INC. | $30.03 | 2023 | Inspire |
| Exact Sciences Corporation | $24.57 | 2025 | The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $21.91 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Intuitive Surgical, INC. | $18.96 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.88 | 2025 | Nuzyra, Xhance |
| Biohaven Pharmaceuticals, INC. | $16.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.21 | 2023 | Camzyos |
| Rti Surgical, INC | $15.51 | 2023 | |
| Abiomed | $14.73 | 2023 | Impella |
| Alvogen INC | $13.62 | 2022 | |
| Eisai INC. | $12.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Starr Whittaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.